Aldeyra Therapeutics (ALDX) versus The Competition Critical Survey

Aldeyra Therapeutics (NASDAQ: ALDX) is one of 306 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Aldeyra Therapeutics to related companies based on the strength of its dividends, earnings, valuation, profitability, risk, analyst recommendations and institutional ownership.

Earnings and Valuation



This table compares Aldeyra Therapeutics and its competitors gross revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Aldeyra Therapeutics N/A -$18.69 million -4.22
Aldeyra Therapeutics Competitors $290.00 million $35.57 million 148.42

Aldeyra Therapeutics’ competitors have higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

40.3% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 49.9% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 28.4% of Aldeyra Therapeutics shares are owned by insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and target prices for Aldeyra Therapeutics and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aldeyra Therapeutics 0 0 5 0 3.00
Aldeyra Therapeutics Competitors 790 3131 11432 227 2.71

Aldeyra Therapeutics presently has a consensus target price of $19.40, suggesting a potential upside of 226.05%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.84%. Given Aldeyra Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Aldeyra Therapeutics is more favorable than its competitors.

Risk & Volatility

Aldeyra Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Aldeyra Therapeutics’ competitors have a beta of 5.89, suggesting that their average share price is 489% more volatile than the S&P 500.

Profitability

This table compares Aldeyra Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aldeyra Therapeutics N/A -82.39% -72.28%
Aldeyra Therapeutics Competitors -5,315.64% -487.41% -42.72%

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company’s aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.

Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply